Evidence map›Paper›PMID 35092634›Full record

ArticleHelicobacter2022

GM-CSF is key in the efficacy of vaccine-induced reduction of Helicobacter pylori infection.

Laurie Vaillant, Paul Oster, Brynn McMillan, Eulalia Orozco Fernandez, Dominique Velin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Helicobacter, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Vaccines · 2025
    Review
  2. Article
  3. Helicobacter pylori infection.Nature reviews. Disease primers · 2023
    Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Laurie VaillantService of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Paul OsterService of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Brynn McMillanService of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Eulalia Orozco FernandezService of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Dominique VelinService of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0001-6033-5871
University Hospital of Lausanne · CH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030-173197
6 · The paper itself

Abstract

backgroundHelicobacter pylori (H. pylori) colonizes the human gastric mucosa with a high worldwide prevalence. Currently, H. pylori is eradicated by the use of antibiotics. However, elevated antibiotic resistance suggests new therapeutic strategies need to be envisioned: one approach being prophylactic vaccination. Pre-clinical and clinical data show that a urease-based vaccine is efficient in decreasing H. pylori infection through the mobilization of T helper (Th) cells, especially Th17 cells. Th17 cells produce interleukins such as IL-22 and IL-17, among others, and are key players in vaccine efficacy. Recently, granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing Th17 cells have been identified.

aimThis study explores the possibility that GM-CSF plays a role in the reduction of H. pylori infection following vaccination.

resultsWe demonstrate that GM-CSF

conclusionTaken together, we demonstrate a key role of GM-CSF, most probably originating from Th17 cells, in the vaccine-induced reduction of H. pylori infection.

Indexed as

Bacterial VaccinesGranulocyte-Macrophage Colony-Stimulating FactorHelicobacter InfectionsHelicobacter pyloriAnimalsMiceTh17 CellsVaccinationBacterial VaccinesGranulocyte-Macrophage Colony-Stimulating Factorantimicrobial peptidedefensinGM-CSFHelicobacter pyloriTh17 responsevaccine

Identifiers

PMID35092634
PMCPMC9285700
OpenAlexW4210299354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.